Nasdaq Delisting Notice Hits Quince Therapeutics on Negative Equity
QNCX has more than doubled off its 52-week low of $15.1 on light trading volume (0.4× avg).
Summary
Quince Therapeutics received a Nasdaq delisting notice for negative stockholders' equity of $35.3 million, with a compliance plan due by October 15, 2026.
Key Events · Legal and Risk Events · QNCX
-
Nasdaq Delisting Notice Received
On August 31, 2026, Nasdaq notified Quince Therapeutics that its stockholders' equity of ($35,324,000) as of June 30, 2026 falls below the $10,000,000 minimum required by Listing Rule 5450(b)(1)(A).
-
Compliance Plan Deadline
The company has 45 days, until October 15, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 days, until February 27, 2027, to evidence compliance.
-
Listing Alternatives Under Evaluation
Quince is evaluating alternatives including a Nasdaq Capital Market listing under the new name 'IRulya Therapeutics Inc.' and symbol 'IRLA', contingent on approval of the Initial Listing Application and Required Company Stockholder Matters.
-
Going Concern and Equity Conversion Context
The delisting notice follows the company's Q2 10-Q disclosing substantial doubt about its ability to continue as a going concern, and precedes an October 6 shareholder vote on converting Series C Preferred Stock into 10.99 million common shares, which could improve equity.
Analysis · QNCX · Life Sciences
A Nasdaq delisting notice now compounds the distress at Quince Therapeutics. The company disclosed on September 4 that Nasdaq had notified it on August 31 of non-compliance with the $10 million minimum stockholders' equity requirement, citing negative equity of $35.3 million as of June 30, 2026. A compliance plan is due by October 15, with a possible extension to February 27, 2027 if accepted. This development arrives alongside an already disclosed going-concern warning and a pending October 6 shareholder vote on converting Series C Preferred Stock into 10.99 million common shares — a transaction that could materially improve equity if approved. The delisting notice adds immediate listing risk to an already distressed situation, though the company is pursuing a Nasdaq Capital Market listing under a new name and symbol as a fallback.
How filings like this one have moved
In the 30 days to Sep 7, 2026, 45.2% of the 628 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $30.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.1M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.